Asia Pacific Active Pharmaceutical Ingredient Cdmo Market Size & Outlook
Asia Pacific active pharmaceutical ingredient cdmo market, 2018-2030 (US$M)
Related Markets
Asia Pacific active pharmaceutical ingredient cdmo market highlights
- The Asia Pacific active pharmaceutical ingredient cdmo market generated a revenue of USD 44,672.2 million in 2023.
- The market is expected to grow at a CAGR of 8% from 2024 to 2030.
- In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2023.
- Antibody Drug Conjugate (ADC is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 44,672.2 million |
| Market revenue in 2030 | USD 76,520.1 million |
| Growth rate | 8% (CAGR from 2023 to 2030) |
| Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
| Fastest growing segment | Antibody Drug Conjugate (ADC |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
| Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 37.7% of the global active pharmaceutical ingredient cdmo market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 76,520.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Active Pharmaceutical Ingredient CDMO Market Scope
Active Pharmaceutical Ingredient CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific active pharmaceutical ingredient cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.89% in 2023. Horizon Databook has segmented the Asia Pacific active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific’s active pharmaceutical ingredient CDMO market is expected to witness lucrative growth over the forecast period, owing to the increasing scope of opportunities, especially in Japan, China, and India. It accounted for 46.4% of the global market in 2020.
Furthermore, availability of skilled workforce at a lower cost than developed economies, such as the U.S., is anticipated to propel the market. China holds the largest share in Asia Pacific market, primarily due to high pharmaceutical R&D investment.
Asia Pacific has a number of regulatory agencies, such as Pharmaceuticals and Medical Devices Agency (PMDA) in Japan; the Ministry of Food and Drug Safety (MFDS) in South Korea; and the Therapeutic Goods Administration (TGA) in Australia.
Reasons to subscribe to Asia Pacific active pharmaceutical ingredient cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific active pharmaceutical ingredient cdmo market databook
-
Our clientele includes a mix of active pharmaceutical ingredient cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific active pharmaceutical ingredient cdmo market size, by country, 2018-2030 (US$M)
Asia Pacific Active Pharmaceutical Ingredient CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
